Quarterly ResultMay 14, 2026, 05:33 PM
Propanc Biopharma Q3 Net Loss $(6.36)M; Cash $443.7K
AI Summary
Propanc Biopharma, Inc. reported a net loss of $(6.36) million for the three months ended March 31, 2026, a significant improvement from $(54.07) million in the prior year period. For the nine months ended March 31, 2026, the net loss was $(14.29) million, down from $(54.85) million year-over-year. The company's cash position improved substantially to $443,702, up from $12,088 at June 30, 2025, driven by financing activities including proceeds from common stock sales and Series C preferred stock and warrant exercises.
Key Highlights
- Net loss for Q3 2026 significantly reduced to $(6.36) million from $(54.07) million in Q3 2025.
- Nine-month net loss improved to $(14.29) million from $(54.85) million year-over-year.
- Basic and diluted net loss per share for Q3 2026 was $(0.28), compared to $(12.50) in Q3 2025.
- Cash balance increased to $443,702 at March 31, 2026, from $12,088 at June 30, 2025.
- Total assets decreased to $14.33 million, while total liabilities decreased to $3.51 million.
- Net cash used in operating activities for the nine months was $(4.08) million.
- Raised $3.31 million from common stock sales and $1.00 million from Series C warrant exercise.